HBV-ISS Dynavax

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 2, 2006, Pages 150-155

  Sung, Joseph Jao Yiu ^a   Chan, Henry Lik Yuen ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPLISAV; POLYMYXIN B; RECOMBINANT ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; TOLL LIKE RECEPTOR 9;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ARTHRALGIA; CHILL; CLINICAL TRIAL; CYTOKINE RELEASE; DIARRHEA; DNA SEQUENCE; DRUG CONTRAINDICATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SYNTHESIS; FATIGUE; HEPATITIS B; HUMAN; IMMUNOSTIMULATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LICENCE; MYALGIA; NAUSEA; NONHUMAN; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION; VACCINATION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADULT; CLINICAL TRIALS, PHASE III; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INJECTIONS, SUBCUTANEOUS; TIME FACTORS; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 33645711793     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. 73 Drug development pipeline: Hepagene, methylphenidate MR Chiral, MR-methylphenidate, bismuth, Medeva, nicotine (controlled release), Celltech. Medeva Plc COMPANY COMMUNICATION 1997 January 23
2. 10 Vaccines to prevent viral hepatitis. Lemon SM, Thomas DL N ENGL J MED 1997 336 3 196-204
3. 86 Human trials for oral hepatitis B plant vaccine begin in United States. Axis Genetics plc PRESS RELEASE 1999 July 08
4. 69 Triangle and Dynavax sign viral disease research deal. Triangle Pharmaceuticals Inc PRESS RELEASE 2000 April 04
5. 57 Celitech Group plc sale of Celltech Medeva's vaccines business. Celltech Group plc PRESS RELEASE 2000 September 07
6. 17 Corixa begins phase III RC-529 trial. Corixa Corp PRESS RELEASE 2001 January 12
7. 22 Linking immunostimulatory DNA to HBsAg dramatically increases T cell responses in mice. TraQuina P, Abbate C, Eiden J, Higgins D, Patton K Ramirez K, Rodriguez R, Tuck S, Van Nest G/CAAC 2001 41 Abs G-1579
8. 86 Dynavax Technologies and Triangle Pharmaceuticals announce positive hepatitis B prophylaxis data at ICAAC. Dynavax Technologies Corp PRESS RELEASE 2001 December 18
9. 11 An immunostimulatory oligonucleotide (ISS-ODN) enhances immune responses to HBV vaccine in a variety of animal species including primates. Van Nest G, Tighe H, Raz E, Higgins D, Traquina P, Eiden J/ CAAC 1999 39 Abs 679
10. 03 Dynavax starts phase II trial of HBV vaccine. Dynavax Technologies Corp PRESS RELEASE 2002 September 04
11. 71 Modern Vaccines Adjuvants and Delivery Systems - MVADS 2003 (Part II), Dublin, Ireland. Ulmer J IDDB MEETING REPORT 2003 June 4-6
12. 66 Recommended cash offer by UBS Investment Bank on behalf of Chiron UK-1 Limited a wholly-owned subsidiary of Chiron Corporation and (in the United States) by Chiron UK-1 Limited for PowderJect Pharmaceuticals plc. Chiron Corp PRESS RELEASE 2003 July 08
13. 16 Dynavax and University of California announce issuance of broad patent covering ISS linked to allergens and antigens. Dynavax Technologies Corp PRESS RELEASE 2003 August 27
14. 72 Polymyxin formulation enhances the adjuvant effect of immunostimulatory DNA. dela Cruz T, Ott G, Higgins D, Teshima G, Marshall J, Abbate C, Tuck S, Van Nest G/CAAC 2003 43 Abs G-278
15. 61 SUPERVAX HBV vaccine approved in Argentina. Corixa Corp PRESS RELEASE 2003 September 09
16. 72 Dynavax initiates phase II/III HBV vaccine trial. Dynavax Technologies Corp PRESS RELEASE 2004 June 22
17. 85 Immunization underway in Dynavax's HBV vaccine trial. Dynavax Technologies Corp PRESS RELEASE 2004 September 02
18. 82 Immunostimulatory oligonucleotide (ISS ODN) co-injection enhances protective antibody response to Hepatitis B surface antigen (HBsAg) and is well-tolerated by seronegative individuals. Halperin SA, Van Nest G, Halperin B, Smith B, Abtahi S, Whiley H, Eiden J/CAAC 2001 41 Abs 1578
19. 97 Novel chimeric Immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells. Marshall JD, Hessel EM, Gregorio J, Abbate C, Yee P, Chu M, Van Nest G, Coffman RL, Fearon KL NUCLEIC ACIDS RES 2003 31 17 5122-5133
20. 98 IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. Duramad O, Fearon KL, Chan JH, Kanzler H, Marshall JD, Coffman RL, Barrat FJ BLOOD 2003 102 13 4487-4492
21. 99 A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ VACCINE 2003 21 19-20 2461-2467
22. 58 Dynavax's hepatitis B vaccine shows more rapid immunogenicity, more durable protective response than Engerix-B in phase 2 clinical trial. Dynavax Technologies Corp PRESS RELEASE 2004 November 01
23. 83 Microscience's oral HBV vaccine shows promise in phase I trial. Microscience Ltd PRESS RELEASE 2004 November 03
24. 99 Dynavax's HBV vaccine superior to GSK's Engerix B. Dynavax Technologies Corp PRESS RELEASE 2004 December 09
25. 40 Dynavax Technologies Corp: Form 10-K for the year ended 31 December 2003. Dynavax Technologies Corp FORM 10-K 2004 March 30
26. 24 Sci-B-Vac: Recombinant hepatitis B vaccine. SciGen Ltd COMPANY WORLD WIDE WEB SITE 2005 March 17
27. 55 Dynavax announces positive primary endpoint results from phase 2/3 hepatitis B vaccine trial. Dynavax Technologies Corp PRESS RELEASE 2005 June 14
28. 27 Dynavax starts pivotal trial of HBV vaccine. Dynavax Technologies Corp PRESS RELEASE 2005 June 23
29. 72 Vaxine Pty Ltd. Vaxine Pty Ltd COMPANY WORLD WIDE WEB SITE 2005 September 21
30. 46 Hepatitis B virus infection. Lee WM N ENGL J MED 1997 337 24 1733-1745
31. 55 Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, Hsu HM, Chen HL, Hsu HY, Chen DS J AM MED ASSOC 2000 284 23 3040-3042
32. 87 Dynavax starts HBV vaccine phase I trial in renal failure patients. Dynavax Technologies Corp PRESS RELEASE 2005 November 01
33. 45 Recombinant hepatitis B surface antigen (rHBsAg) co-adminstered with an immunostimulatory phosphorothioate oligonucleotide (1018 ISS) provides superior protection in older subjects. Lim SG, Chow WC, Freeman A, Reading S, Levitt D, Petersen C ICAA C 2005 46 Abs G-846
34. 76 Factors associated with receiving hepatitis B vaccination among high-risk adults in the United States: An analysis of the National Health Interview Survey, 2000. Jain N, Yusuf H, Wortley PM, Euler GL, Walton S, Stokley S FAM MED 2004 36 7 480-486
35. 80 Compliance with hepatitis B virus vaccination and risk of occupational exposure to blood and other body fluids in intensive care department personnel in Brazil. Manso VF, Castro KF, Matos SM, Junqueira AL, Souza SB, Sousa MM, Martins RM, Teles SA AM J INFECT CONTROL 2003 31 7 431-434
36. 82 Immunogenicity of hepatitis B vaccines: Implications of immune memory. Koff RS VACCINE 2002 20 31-32 3695-3701
37. 85 Adherence to hepatitis B virus vaccination at syringe exchange sites. Altice FL, Bruce RD, Walton MR, Buitrago MI J URBAN HEALTH 2005 82 1 151-161
38. 86 Long-term immunogenicity of hepatitis B vaccination and policy for booster: An Italian multicentre study. Zanetti AR, Mariano A, Romano L, D'Amelio R, Chironna M, Coppola RC, Cuccia M, Mangione R, Marrone F, Negrone FS, Parlato A, Zamparo E, Zotti C, Stroffolini T, Mele A, Study Group LANCET 2005 366 9494 1379-1384
39. 03 Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, Levitt D, Nest GV, Gennevois D, Eiden JJ VACCINE 2006 24 1 20-26
40. 31 Allergenic components of vaccines and avoidance of vaccination-related adverse events. Georgitis JW, Fasano MB CURR ALLERGY REP 2001 1 1 11-17